The global single domain antibody platform market is booming, driven by increased healthcare R&D and the platforms’ efficacy in treating various diseases. This report projects market growth to US$ 86 million by 2034, with significant contributions from North America and East Asia. Leading players are driving innovation, but access to camelids, the primary source of these antibodies, remains a challenge.
The global psoriasis drug market is experiencing explosive growth, projected to reach US$27.57 billion by 2034. Driven by increasing prevalence, R&D investment, and innovative treatments, this market analysis reveals key trends, leading players, and future projections.
Amgen’s MariTide, a potential new obesity treatment, showed promising weight loss in Phase 2 trials, but fell short of Wall Street expectations, causing a significant drop in AMGN stock price. The drug demonstrated up to 20% weight loss but lacked the 25% some analysts predicted.
Biotech company Unnatural Products (UNP) announced the appointment of Simon Bailey, Ph.D., as its new Chief Operating Officer and President of R&D. Dr. Bailey brings over 25 years of experience in drug discovery and development to lead UNP’s growth in macrocyclic therapeutics, a promising new area of drug development.
A Cantor analyst highlighted potential bone density concerns with Amgen’s MariTide, a promising weight loss drug. The analyst pointed to data from a Phase 1 study showing a decrease in bone mineral density at the highest dose. However, Amgen and Goldman Sachs have downplayed the concerns, citing other data and the common occurrence of BMD reduction with rapid weight loss. The stock experienced a dip but recovered, with analysts remaining optimistic about MariTide’s potential.
Pharmaceutical giant Johnson & Johnson (JNJ) has filed a lawsuit against a US government agency over a dispute concerning the 340B Drug Pricing Program. J&J argues that the program has been exploited by entities not intended as beneficiaries, leading to abuses that undermine patient benefits. The lawsuit centers around J&J’s proposed rebate-based pricing model, which aims to improve program transparency and curb duplicate discounting. However, the government agency responsible for overseeing the program, HRSA, has resisted the plan, leading to the legal action.
The global monochloroacetic acid (MCA) market is set to experience robust growth, driven by its critical role in various industries. This report provides a comprehensive analysis of the MCA market, outlining key drivers, emerging trends, and regional dynamics. Discover the potential of MCA in advanced materials, water treatment, and sustainable manufacturing.
The global ELISA analyzers market is poised for significant growth, projected to reach $960.7 million by 2031, driven by technological advancements, increasing demand for sophisticated diagnostic tools, and a rising prevalence of chronic diseases. This report provides a comprehensive analysis of the market’s key drivers, trends, segmentation, and leading players.
Univar Solutions has partnered with SD Head USA, a leading global manufacturer of cellulose ethers and plant-based capsules, to become the exclusive distributor of their pharmaceutical excipients across North America. This strategic alliance will expand Univar Solutions’ product offerings and provide access to a wide range of high-quality cellulose ethers, including methylcellulose (MC), ethylcellulose (EC), sodium carboxymethyl cellulose (CMC-Na), and hydroxypropyl methylcellulose (HPMC).
CERo Therapeutics Holdings, Inc. (CERO) stock surged over 150% on Monday after the company presented preclinical data showing its lead compound, CER-1236, effectively kills ovarian cancer cells in preclinical models without causing toxicity. The positive results, coupled with the potential for orphan drug designation, have ignited investor enthusiasm.
